Compare Enveric Biosciences Inc (ENVB) vs EPR Properties (EPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs EPR Properties — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while EPR Properties trades at $54.41 (market cap $4.17B). The key difference: EPR Properties is far larger — about 613.2× Enveric Biosciences Inc's market cap, and EPR Properties pays a 6.84% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and EPR Properties for 45 Days on average.
| ENVB | EPR | |
|---|---|---|
Market Cap | $6.80M | $4.17B |
Volume | 64,867 | 992,716 |
Sector | Health | Real Estate |
52-Week High | $10.80 | $64.32 |
52-Week Low | $1.27 | $48.71 |
Typical Hold Time | 14 Days | 45 Days |
Enterprise Value | -$1.49M | $7.68B |
Dividend Yield | — | 6.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
EPR Properties trades at $54.08, down 2.15% on the day, with a bearish technical signal. The REIT maintains strong fundamentals, including a 91.41% gross margin and a 37.66% net income margin, though net income is projected to dip slightly in 2026. Recent news highlights its focus on monthly dividends and diversification beyond theaters into experiential properties.
The outlook is mixed; analyst consensus is a 'Buy' with a $65.50 price target, suggesting significant upside, but technical indicators and a recent earnings miss signal near-term caution. Key risks include exposure to interest rate sensitivity and execution of its diversification strategy amidst a bearish market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →
